This clinical trial studies the antibody-drug conjugate gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) in treating patients with relapsed or refractory acute myeloid leukemia or acute promyelocytic leukemia (APL). Monoclonal antibodies, such as gemtuzumab ozogamicin, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. This trial is sponsored by the Comprehensive Cancer Center of Wake Forest University. 
- Adult Myeloid Leukemia (AML)
- Adult Acute Promyelocytic Leukemia (M3)
- Childhood Acute Promyelocytic Leukemia (M3)
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Childhood Acute Myeloid Leukemia
- Phase: 0
- Estimated Enrollment: 30
- Start: August 2013
- Estimated Primary Completion: August 2020
- Last verified: July 2014
Last Editorial review: July 17, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.